NCT00219739View on ClinicalTrials.gov

STI571 ProspectIve RandomIzed Trial: SPIRIT

PHASE3CompletedINTERVENTIONAL
Enrollment

789

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Chronic Myeloid Leukemia
Interventions
DRUG

Imatinib mesylate 400 mg

DRUG

Imatinib mesylate 600 mg

DRUG

Imatinib 400 mg + Peg-Interferon

DRUG

Imatinib mesylate 400 mg + Cytarabine

Trial Locations (1)

86021

University Hospital, Poitiers

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Ministry of Health, France

OTHER_GOV

collaborator

Novartis

INDUSTRY

collaborator

Roche Pharma AG

INDUSTRY

lead

Poitiers University Hospital

OTHER

NCT00219739 - STI571 ProspectIve RandomIzed Trial: SPIRIT | Biotech Hunter | Biotech Hunter